It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The metabolic checkpoint kinase mechanistic/mammalian target of rapamycin (mTOR) regulates natural killer (NK) cell development and function, but the exact underlying mechanisms remain unclear. Here, we show, via conditional deletion of Raptor (mTORC1) or Rictor (mTORC2), that mTORC1 and mTORC2 promote NK cell maturation in a cooperative and non-redundant manner, mainly by controlling the expression of Tbx21 and Eomes. Intriguingly, mTORC1 and mTORC2 regulate cytolytic function in an opposing way, exhibiting promoting and inhibitory effects on the anti-tumor ability and metabolism, respectively. mTORC1 sustains mTORC2 activity by maintaining CD122-mediated IL-15 signaling, whereas mTORC2 represses mTORC1-modulated NK cell effector functions by restraining STAT5-mediated SLC7A5 expression. These positive and negative crosstalks between mTORC1 and mTORC2 signaling thus variegate the magnitudes and kinetics of NK cell activation, and help define a paradigm for the modulation of NK maturation and effector functions.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Li, Xiaohui 1
; Deng, Youcai 1
1 Institute of Materia Medica, College of Pharmacy, Army Medical University (Third Military Medical University), Chongqing, China
2 Department of Laboratory Medicine, PLA 307 Hospital, Beijing, China
3 Institute of Blood and Marrow Transplantation, Soochow University, Suzhou, China
4 Institute of Materia Medica, College of Pharmacy, Army Medical University (Third Military Medical University), Chongqing, China; Colleges of Pharmacy and Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada
5 The Ohio State University Comprehensive Cancer Center and the James Cancer Hospital, Columbus, OH, USA
6 Institute of Immunology, Army Medical University (Third Military Medical University), Chongqing, China
7 The Ohio State University Comprehensive Cancer Center and the James Cancer Hospital, Columbus, OH, USA; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA




